Experts Reach Consensus on IBS Management

JUNE 01, 2003

Irritable bowel syndrome (IBS) is among the most common disorders gastroenterol-ogists and primary care physicians encounter. In the past 10 years, research strides have radically changed how patients with IBS are diagnosed and treated.

Late last year the American College of Gastroenterology Functional Gastrointestinal Disorders Task Force developed a consensus document, An Evidence-Based Position Statement and Systematic Review on the Management of IBS in North America, which was published as a supplement to the American Journal of Gastroenterology. The aim of this document is to equip physicians with practical resources they can use to diagnose, treat, and manage IBS patients in their clinical practices.

The task force gave the highest recommendations (based on supporting evidence and quality of clinical trials) to the only 2 approved treatments for the multiple symptoms of IBS:

  • Tegaserod, indicated for the short-term treatment of women with IBS whose primary bowel symptom is constipation, and
  • Alosetron, indicated for the treatment of women with severe diarrhea-predominant IBS who have failed conventional IBS therapy.


SHARE THIS SHARE THIS
0
 

The Oncology Care Pharmacist in Health-System Pharmacy 
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.


 

Pharmacy Times Strategic Alliance
 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.